Results 311 to 320 of about 1,398,610 (367)

E-006

Epidemiology, 2012
Laura Zheng, Jason Umans, Maria Tellez-Plaza, Barbara Howard, Fawn Yeh, Kevin Francesconi, Walter Goessler, Ellen Silbergeld, Eliseo Guallar, Virginia Weaver, Ana Navas-Acien   +10 more
openaire   +1 more source

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

The Lancet, 2017
J. Schachter, A. Ribas, G. Long, A. Arance, J. Grob, L. Mortier, A. Daud, M. Carlino, C. McNeil, M. Lotem, J. Larkin, P. Lorigan, B. Neyns, C. Blank, T. Petrella, O. Hamid, Honghong Zhou, S. Ebbinghaus, N. Ibrahim, C. Robert   +19 more
semanticscholar   +1 more source

P-006

Epidemiology, 2012
Ji-Young Lee, Jong-Han Leem, Eun-Hee Ha, Kim Hwan-Cheol, Myung-Sook Park, Dal-Young Chung, Kim Jung-Ae, Kweon Jung, Nam-Jin Kim, Hyesook Park, Mina Ha, Yangho Kim, Seung-Do Yu, Chulwoo Lee   +13 more
openaire   +1 more source

Bronx Project-006-A, (BP-006-A)

2022
openaire   +1 more source

Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study.

Annals of Oncology
G. V. Long, M. Carlino, C. McNeil, A. Ribas, C. Gaudy-Marqueste, J. Schachter, M. Nyakas, D. Kee, T. Petrella, A. Blaustein, M. Lotem, A. Arance, A. Daud, O. Hamid, J. Larkin, L. Yao, R. Singh, R. Lal, C. Robert   +18 more
semanticscholar   +1 more source

4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.

, 2018
G. Long, J. Schachter, A. Ribas, A. Arance, J. Grob, L. Mortier, A. Daud, M. Carlino, C. McNeil, M. Lotem, J. Larkin, P. Lorigan, B. Neyns, C. Blank, T. Petrella, O. Hamid, James R. Anderson, C. Krepler, N. Ibrahim, C. Robert   +19 more
semanticscholar   +1 more source

10.1037/e531892012-006

CrossRef Listing of Deleted DOIs, 2000
openaire   +1 more source

10.1037/e608062007-006

CrossRef Listing of Deleted DOIs, 2000
openaire   +1 more source

10.1037/e694252011-006

CrossRef Listing of Deleted DOIs, 2000
openaire   +1 more source

Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment.

, 2017
C. Robert, G. Long, J. Schachter, A. Arance, J. Grob, L. Mortier, A. Daud, M. Carlino, C. McNeil, M. Lotem, J. Larkin, P. Lorigan, B. Neyns, C. Blank, T. Petrella, O. Hamid, Honghong Zhou, B. H. Moreno, N. Ibrahim, A. Ribas   +19 more
semanticscholar   +1 more source